Hvivo

Company, formerly known as Open Orphan, described the first half of 2023 as ‘another period of excellent growth’

Dublin- and London-listed pharma services company has seen its order book grow 11% in first half from same period in 2022

Deal is Dublin-listed pharma company's first in the region in over 10 years

Company expects revenues from the contract to be recognised across 2022 and 2023

Bavarian Nordic vaccine candidate used hVivo challenge trial to gather data

Executive chairman Cathal Friel said Hvivo expects to sign a number of similar contracts

Healthy volunteers are administered a pathogenic or virulent strain of virus

hVivo will develop a new SARS-CoV-2 challenge virus based on new emerging variants

Contract with US biotechnology company concerns a respiratory syncytial virus

Irish clinical trials group will deliberately infect healthy young volunteers with virus

Guidelines will cover manufacture of agents for use in controlled infection studies

Contract with UK government could be worth up to £10m

Open Orphan’s hVivo unit will conduct world’s first human challenge trials of several vaccine candidates

Dublin listed company will carry out phase one trial at Hvivo facility